ASH 2017: Mixed results for new NHL therapies
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.
Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar… read more.
Professor Peter Johnson (Southampton, UK) tells us what’s new with response-adapted therapy and what are the benefits to patients.
Men who have received initial treatment for prostate cancer with abiraterone added to hormone therapy achieved a survival rate 37 per cent higher than those not treated with… read more.
Interviewer: Esther Drain Dr Toby Eyre (Oxford), Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell… read more.
By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.
The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.
Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.
Chronic, cancer-related fatigue (CRF) is associated with a sudden- onset, profound lack of energy that is not relieved by rest. It is different from the fatigue experienced by… read more.
Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.